2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-170816
    CYP51/Hsp90-IN-1 98%
    CYP51/Hsp90-IN-1 (Compound MM4) is a dual CYP51/Hsp90 inhibitor. CYP51/Hsp90-IN-1 shows antifungal activity against Candida albicans and effectively inhibits important fungal virulence factors. CYP51/Hsp90-IN-1 is promising for research of invasive candidiasis.
    CYP51/Hsp90-IN-1
  • HY-170819
    VK13 98%
    VK13 (Compound 6) is a potent inhibitor of human cathepsin L (hCatL) with a Ki value of 0.55 nM and SARS-CoV-2 3CLpro (3CL-PR) with a Ki value of 2.6 nM. VK13 exhibits anti-CoV-2 activity with an EC50 of 1.25 μM.
    VK13
  • HY-170830
    Mtb against-1 98%
    Mtb against-1 (compound 17af) is an inhibitor of Mycobacterium tuberculosis, with IC90 values of 1.2 μM and 0.9 μM for the wild-type and LepB low-deformation strains, respectively.
    Mtb against-1
  • HY-170835
    NDM-1 inhibitor-7 26151-73-5 98%
    NDM-1 inhibitor-7 (Compound A8) is a NDM-1 inhibitor, with IC50 of 10.284 μM. NDM-1 inhibitor-7 restores the ability of MEM to penetrate the cell wall of gram-negative bacteria. NDM-1 inhibitor-7 effectively restores the antibacterial activity of MEM against NDM-1-positive Escherichia coli. NDM-1 inhibitor-7 demonstrates strong efficacy in both the Galleria mellonella infection model and murine peritonitis infection model.
    NDM-1 inhibitor-7
  • HY-170840
    Antimalarial agent 47 98%
    Antimalarial agent 47 (compound F14) is an antimalarial compound, with an IC50 of 235 nM for the Plasmodium falciparum W2 strain.
    Antimalarial agent 47
  • HY-170847
    Anti-MRSA agent 24 2379890-92-1 98%
    Anti-MRSA agent 24 (compound 6K) is an antimicrobial agent that targets Staphylococcus aureus (MRSA), especially penicillin-resistant Staphylococcus aureus.
    Anti-MRSA agent 24
  • HY-170848
    Antimalarial agent 48 2035422-63-8 98%
    Antimalarial agent 48 (Compound 15a) is a triazine-class compound with antimalarial activity, showing inhibitory concentrations of 280 nM against Plasmodium falciparum K1 and 290 nM against Plasmodium falciparum FCR3. Antimalarial agent 48 is expected to be useful for research in the field of antimalarial infections.
    Antimalarial agent 48
  • HY-170885
    Group II intron-IN-1 836644-25-8 98%
    Group II intron-IN-1 (Compound 1) is an inhibitor of fungal Group II introns, with an IC50 of 3 μM. Group II intron-IN-1 can be used for research on infections caused by fungi such as Candida.
    Group II intron-IN-1
  • HY-170886
    SARS-CoV-2 Mpro-IN-36 98%
    SARS-CoV-2 Mpro-IN-36 (Compound 6d) is an inhibitor of SARS-CoV-2 Mpro with an IC50 of 110 nM. SARS-CoV-2 Mpro-IN-36 exhibits antiviral activity with an EC50 of 1.6 μM.
    SARS-CoV-2 Mpro-IN-36
  • HY-170894
    SARS-CoV-2 Mpro-IN-37 98%
    SARS-CoV-2 Mpro-IN-37 (compound 8r) is a SARS-CoV-2 main protease (Mpro) inhibitor, with an IC50 of 0.0199 μM. SARS-CoV-2 Mpro-IN-37 inhibits SARS-CoV-1 Mpro and MERS-CoV Mpro with IC50s of 0.00945 and 0.111 μM, respectively. SARS-CoV-2 Mpro-IN-37 displays high antiviral activity in the nanomolar range without showing cellular toxicity.
    SARS-CoV-2 Mpro-IN-37
  • HY-170922
    SARS-CoV-2-IN-110 98%
    SARS-CoV-2-IN-110 (compound Bb1) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-110 exhibits antiviral efficacy against SARS-CoV-2 with an EC50 of 1.10 μM and significantly lower toxicity compared to Lapatinib (HY-50898). SARS-CoV-2-IN-110 inhibits SARS-CoV-2 with a CC50 of > 100 μM, with a selectivity index (SI) of >91.
    SARS-CoV-2-IN-110
  • HY-170937
    Urease-IN-20 2998940-98-8 98%
    Urease-IN-20 (compound XBP2) is an inhibitor of Helicobacter pylori (H. pylori). Urease-IN-20 inhibits H. pylori with an IC50 of 0.14 μM. Urease-IN-20 reduces cell Apoptosis and decreases ROS and γH2AX in GES-1 cells infected with H. pylori. Urease-IN-20 exhibits significant gastric mucosal protective effects. Urease-IN-20 shows the potential for H. pylori research.
    Urease-IN-20
  • HY-170940
    Dyrk1A-IN-12 2243701-11-1 98%
    Dyrk1A-IN-12 (compound S43) is a Dyrk (Dual specificity tyrosine phosphorylation regulated kinase 1A inhibitor. Dyrk1A-IN-12 inhibits Dyrk1A with a IC50 of 95 nM. Dyrk1A-IN-12 shows anti-EV-A71 activity with an EC50 of 4.4 μM, CC50 of 12.8 μM and SI of 2.9. Dyrk1A-IN-12 shows potent inhibition against herpes simplex virus (HSV).
    Dyrk1A-IN-12
  • HY-170963
    LASSBio-1985 98%
    LASSBio-1985 is an NHLd inhibitor (nucleoside hydrolase from Leishmania donovani), with a Ki of 79 μM and an IC50 of 84.6 μM. LASSBio-1985 exhibits selective toxicity against Leishmania parasites, with no toxicity to mammalian cells, making it a promising candidate for research in the field of anti-infective therapies.
    LASSBio-1985
  • HY-170969
    HIV-1 inhibitor-81 98%
    HIV-1 inhibitor-81 (Compound 14g) is an HIV-1 protease inhibitor with a Ki of 1.6 nM. HIV-1 inhibitor-81 exhibits certain antiviral activity, with an EC50 of 250 nM for HIV-1.
    HIV-1 inhibitor-81
  • HY-170970
    Mtb-IN-10 98%
    Mtb-IN-10 (Compound P15) is a Rv1625c/Cya activator that regulates cAMP metabolism to influence the growth of Mycobacterium tuberculosis (Mtb). Mtb-IN-10 exhibits an EC50 of 1.96 µM in an Mtb-infected macrophage model and demonstrates 58.0% oral bioavailability in mice at a 20 mg/kg dose. It may regulate intracellular signaling and disrupt cholesterol metabolism in Mtb, thereby inhibiting bacterial proliferation. Mtb-IN-10 holds potential for tuberculosis (TB) research, particularly for combating multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) Mtb strains.
    Mtb-IN-10
  • HY-170974
    SDH-IN-20 98%
    SDH-IN-20 (compound A19) is an antifungal agent. SDH-IN-20 against Verticillium dahlia, R. solani with EC50s of less than 3.0 μg/mL, 2.87 μg/mL. SDH-IN-20 exerts its highly antifungal effects by acting as an effective succinate dehydrogenase (SDH) inhibitor with an IC50 of 29.33 μM. SDH-IN-20 adversely impacts the integrity of cell membranes and mycelial morphologies of R. solani.
    SDH-IN-20
  • HY-170991
    C12-rrw-NH2 98%
    C12-rrw-NH2 (Compound Lip7) is an antibacterial agent against gram-positive bacteria, especially against Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA). C12-rrw-NH2 induces bacterial death via depolarizing the bacterial cytoplasmic membrane, disrupting the integrity of the bacterial membrane, leading to leakage of nucleic acid and protein and promoting the generation of Reactive Oxygen Species. C12-rrw-NH2 is potential to be used for research of developing high-stability antimicrobial peptides.
    C12-rrw-NH2
  • HY-170993
    Antimicrobial agent-39 98%
    Antimicrobial agent-39 (Compound 8i) is an antibiotic that targets 50S ribosomal subunit and inhibits bacterial protein synthesis. Antimicrobial agent-39 disrupts bacterial cell membranes, leads to leakage of cell contents, thereby exhibiting board-spectrum actibacterial activity. Antimicrobial agent-39 targets organic cation transporters (OCTs), accumulates in infected kidneys, thereby ameliorating pyelonephritis in mouse models.
    Antimicrobial agent-39
  • HY-171005
    VPC162134 1245813-92-6 98%
    VPC162134 is an antibacterial agent, that inhibits H. pylori, C. jejuni, MRSA and S. epidermidis with MIC of 2.9, 17.5, 93.3 and 93.3 μM. VPC162134 is an inhibitor for pyruvate ferredoxin oxidoreductase (PFOR).
    VPC162134
Cat. No. Product Name / Synonyms Application Reactivity